

LONG-TERM FOLLOW-UP OF HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON ALFA: RELATION TO POLYMORPHISMS IN IL28B AND APOLIPOPROTEIN E LOCI (INTERFERLONG STUDY)

Published: 12-03-2013

Last updated: 01-05-2024

investigate the relationship between il28b and apolipoproteine E genotype and response to interferon

Ethical review	Approved WMO
Status	Pending
Health condition type	Hepatic and hepatobiliary disorders
Study type	Observational invasive

Summary

ID

NL-OMON39063

Source

ToetsingOnline

Brief title

Response to interferon in hepatitis B: relation to IL28b and Apo E

Condition

- Hepatic and hepatobiliary disorders
- Viral infectious disorders

Synonym

chronic hepatitis B, liver inflammation

Research involving

1 - LONG-TERM FOLLOW-UP OF HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ...
5-05-2025

Human

Sponsors and support

Primary sponsor: Academisch Medisch Centrum

Source(s) of monetary or material Support: Stichting leveronderzoek

Intervention

Keyword: Apolipoprotein E, chronic hepatitis B, IL28b, interferon

Outcome measures

Primary outcome

IL28b & Apo E genotype --> HBeAg and HBsAg loss.

Secondary outcome

-

Study description

Background summary

interferon is an effective treatment for chronic hepatitis B. Unfortunately, only a limited number of patients achieves a response to interferon. IL28b and apolipoprotein E genotypes may predict response.

Study objective

investigate the relationship between il28b and apolipoproteine E genotype and response to interferon

Study design

cross-sectional

Study burden and risks

minimal

Contacts

Public

Academisch Medisch Centrum

's Gravendijkwal 230

Rotterdam 3015CE

NL

Scientific

Academisch Medisch Centrum

's Gravendijkwal 230

Rotterdam 3015CE

NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

chronic hepatitis B

treated with interferon

Exclusion criteria

coinfections with HIV, HCV

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

Recruitment

NL

Recruitment status: Pending

Start date (anticipated): 01-04-2013

Enrollment: 135

Type: Anticipated

Ethics review

Approved WMO

Date: 12-03-2013

Application type: First submission

Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL32192.078.10